Accuracy of the CONTOUR® Blood Glucose Monitoring System

Bern Harrison, B.A., Cheryl Leazenby, B.S., and Solveig Halldorsdottir, Ph.D.

Abstract

Objective:

The aim of the study was to assess the accuracy of the CONTOUR[®] blood glucose monitoring system (BGMS) according to the International Organization for Standardization's International Standard 15197 (ISO 15197:2003) guidelines and to more stringent criteria.

Method:

Finger stick blood samples from 105 subjects with diabetes (25 with type 1, 77 with type 2, and 3 with type unknown) were tested using the CONTOUR BGMS and YSI glucose analyzer.

Results:

99.3% of results were within ISO 15197:2003 criteria (\pm 15 mg/dl of YSI results at glucose concentrations <75 mg/dl and \pm 20% at glucose concentrations >75 mg/dl). Additionally, 96.7% of results were accurate according to more stringent criteria (\pm 15 mg/dl of YSI results for glucose concentrations <100 mg/dl and \pm 15% for glucose concentrations >100 mg/dl). Error grid analysis showed that 99.3% and 0.7% of results were within zones A and B, respectively.

Conclusion:

The CONTOUR BGMS exceeded both the minimum acceptable accuracy based on ISO 15197:2003 and the more stringent accuracy criteria.

J Diabetes Sci Technol 2011;5(4):1009-1013

Author Affiliation: Bayer HealthCare LLC, Diabetes Care, Tarrytown, New York

Abbreviations: (CDC) Centers for Disease Control and Prevention, (CI) confidence interval, (FDA) U.S. Food and Drug Administration, (ISO) International Organization for Standardization

Keywords: blood glucose monitoring, CONTOUR, diabetes, self-monitoring of blood glucose

Corresponding Author: Solveig Halldorsdottir, Ph.D., Bayer HealthCare LLC, Diabetes Care, 555 White Plains Road, Tarrytown, NY 10591; email address solveig.halldorsdottir@bayer.com